Incredible New Multiple Sclerosis Drug Ideas. The monoclonal antibody ofatumumab (kesimpta, arzerra), approved by the fda in 2020, targets cells that damage the nervous system. Personalised eid by therapeutic drug monitoring can enable further extension of treatment intervals.
And rituximab, which is marketed in the united states as rituxan ®. May 12, 2021 — researchers have discovered a sugar molecule whose levels are reduced in the blood of patients with particularly severe multiple sclerosis. First used to treat ms in adults, gilenya became the first dmt therapy approved by the fda for use in children with pediatric ms in 2018.
